Italian Medicines Agency Agenzia Italiana del Farmaco

COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis - COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis

Asset Publisher

Asset Publisher

COVID-19 mRNA Vaccines Comirnaty and Spikevax: risk of myocarditis and pericarditis

The Italian Medicines Agency would like to inform you of the following:

  • Cases of myocarditis and pericarditis have been reported very rarely following vaccination with the COVID-19 mRNA Vaccines Comirnaty and Spikevax.
  • The cases primarily occurred within 14 days after vaccination, more often after the second dose and in younger men. 
  • Available data suggest that the course of myocarditis and pericarditis following vaccination is similar to the course of myocarditis and pericarditis in general.  
  • Healthcare professionals should be alert to the signs and symptoms of myocarditis and pericarditis. 
  • Healthcare professionals should advise vaccinated individuals to seek immediate medical attention should they experience chest pain, shortness of breath, or palpitations.


Published on: 19 July 2021

Asset Publisher

Galleria

Cookie Bar

cookie management module

Descrizione cookieBar

Questo sito utilizza cookie tecnici e analytics, necessari al suo funzionamento, per i quali non è richiesto il consenso. Per alcuni servizi aggiuntivi, le terze parti fornitrici, dettagliatamente sotto individuate, possono utilizzare cookies tecnici, analytics e di profilazione. Per saperne di più consulta la PRIVACY POLICY. Per proseguire nella navigazione devi effettuare la scelta sui cookie di terze parti dei quali eventualmente accetti l’utilizzo. Chiudendo il banner attraverso la X in alto a destra rifiuti tutti i cookie di terze parti. Puoi rivedere e modificare le tue scelte in qualsiasi momento attraverso il link "Gestione cookie" presente nel footer.

Social networks
go to beginning of content